Outcome after Acute Head Trauma Needing Neurosurgical Intervention in Patients with Oral Anticoagulants or Anti-Thrombotic Agents

Auer C* and Wurm G

Department of Neurosurgery, Landesnervenklinik Wagner Jauregg, Linz, Austria, Europe

Abstract

Introduction: The benefit-to-risk-ratio of anticoagulation has been discussed over years in the medical literature. Even in minor Traumatic Brain Injury (TBI), anticoagulation can cause an intracranial hemorrhage. However, there is few data in literature on outcome in TBI, anticoagulation and surgery. The aim was to determine the effect of anticoagulation on outcome and mortality after TBI.

Methods: We performed a retrospective review for patients after TBI needing neurosurgical intervention between January 2003 and September 2008. We compared patients with and without anticoagulation, regarding mortality and outcome. Outcome variables were Karnofsky performance score (KPS) and Glasgow outcome scale (GOS). Statistical testing was done by means of Fisher’s exact test and a multiple logit model.

Results: 293 patients met inclusion criteria. 245 (83.6%) were non anticoagulated patients, 48 (16.4%) received oral anticoagulation (OAC) or antithrombotic agents (ATH). Mean age in all patients was 49.3 years.

Prothrombin time (PT), age, type of bleeding, neurological status on admission turned out as significant factors for mortality and outcome. Ranges of odds ratio for mortality went from 0.98 to 44.8, for KPS and GOS from 0.06 to 1.3. Anticoagulation was not a significant predicting factor for worse outcome or mortality (p = 0.886; 0.926; 0.934).

Conclusion: Age, neurological status on admission and compartment of bleeding are still the most significant prognostic factors for outcome after TBI. Low PT, higher age, comatose on admission, intracerebral hemorrhage, acute subdural hematomas and combined intracranial bleeding are factors predicting a worse outcome. Thus, the intensity of anticoagulation is an important factor, but not the use of these drugs itself.

Keywords: Traumatic brain injury; Surgery; Anticoagulation; Anti-thrombotic therapy; Outcome

Introduction

The use of Oral Anticoagulants (OAC) and Anti-thrombotic Medication (ATH) in patients with intermittent atrial fibrillation, other cardiac diseases, diabetes, peripheral vascular disease and other arteriopathic conditions has been proven to be of benefit, and their use is increasing. However, their use comes at risk of severe complications [1,2]. Warfarin for example reduces the risk of stroke by about two-thirds from 5% to 2% per years, but is at a cost of 5-8 serious bleeding events per 1000 patient per year [1]. The benefit to risk ratio of anticoagulation and anti-thrombotic agents has been discussed over years in the medical literature.

Several studies have demonstrated that in case of traumatic brain injury (TBI) anticoagulation and anti-thrombotic therapy is associated with a seven- to ten-fold risk of intracranial hemorrhage [3,4]. Thus, the rate of mortality and morbidity far exceeds the rate in patients with similar head injuries who are not anticoagulated [3]. Additionally to high intensity of anticoagulation advanced age, as well as chronic alcohol abuse, liver disease and other bleeding diathesis, poorly controlled hypertension and poor clinical compliance have been linked to the early or late development of intracranial hemorrhage [3,5]. Even in the setting of minor head trauma, OAC-related intracranial hemorrhage has been noted [3,6-8]. Also Hart et al. [8] reported that even minor trauma is related to intracranial hemorrhage in OAC patients. The prolonged progression of symptoms probably reflects ongoing bleeding due to diminished capacity of clotting.

Rationale of this study

The prevalence of anticoagulation in head trauma has been examined in various studies. Most studies, however excluded the elderly (over 65 years), were not conducted consecutively, were only pilot studies [9], did not include surgical cases or mixed sporadic and traumatic cases [9]. Even though TBI patients with preinjury anticoagulation needing neurosurgical intervention are included in some reports in the published literature, no general statement on outcome and no recommendation for management can be derived from literature for this patient group yet.

Our impression was that anticoagulation therapy played a significant role in patients admitted to our department with head trauma, raising the question whether anticoagulation is influencing surgical strategies and outcome. There also appeared to be further morbidity after initial surgical treatment with an increased rate of re-hemorrhage. This prompted a retrospective review of cases performed at our unit.

This retrospective analysis of a consecutive series of patients with TBI requiring neurosurgical interventions was undertaken to determine the effect of anticoagulation, if any, on outcome and on mortality, and to distinguish this effect from other influencing factors as age, type of bleeding etc.
Material & Methods

Study population and setting

We performed a retrospective single center study including all patients admitted to our department after an acute head trauma with intracranial bleeding, receiving an operation. Patient with head trauma without any operation, but under conservative treatment were excluded. All patients between January 2003 and September 2008 were included. There were 293 patients meeting inclusion criteria. Patients suffering from chronic subdural hemorrhage were excluded.

We specifically included documentation for the presence or absence of anticoagulation or anti-thrombotic therapy. The variables we examined were Prothrombin time (PT), patient age, sex, initial neurological examination, and radiological findings. Initial neurological examination was considered normal, abnormal, if there was documentation of focal weakness, alteration of consciousness, behavior or speech or cranial nerve abnormality and intubated and comatose. Radiological findings included skull fracture, epidural hematoma (EDH), acute subdural hematoma (aSDH), cerebral contusion (CC), intracerebral hematoma (ICH) and combined intracranial bleeding (cIB).

Follow-up time was between 6 months and 5 years. Follow up was determined by medical records and by physical examination, by phonecalls and questionnaire in the survivor group.

Data analysis

In an initial analysis we compared baseline characteristics of patients with and without anticoagulation. For categorical characteristics like sex, neurological status on admission, etc. Fisher’s exact test was used, to compare the mean values of age and PT across the two groups a Student’s t-test (unequal variances) was performed. Statistical significance was defined as a p-value < 0.05.

To investigate the effect of anticoagulation on mortality, GOS and KPS a multiple logit model including all potential predictors and confounders was fitted. Significance of estimated effects was assessed using a Wald test. We report also estimated odds ratios which specify the effect of a covariate on the mortality odds. This is the factor by which mortality is multiplied for an increase of the covariate value by 1 to 91 years. Mean age in group 1 was 73.53 (range 42 – 91) years; mean age in group 2 was 44.67 (range 1 – 88) years (p< 0.001). Ninety three (31.7 %) patients were female and 200 (68.3 %) were male. In group 2, 69 of 245 patients were female (27.9 %), whereas a higher percentage, 24 of 48 (50 %) were female in group 1 (p= 0.004). In both categories we saw significant differences between anti and non-anticoagulated patients.

Comparing anticoagulated and non-anticoagulated patients concerning the neurological status on admission, there were significant differences between them. In group 2 most patients were without any deficit, rather group 1, where most of them were comatose and intubated on admission (Table 2) (p= 0.004).

A CT scan was obtained in all patients. Both groups showed differences in radiological findings. Anticoagulated patients had a trend to aSDH with a total of 70%, whereas patients without anticoagulation did not show a tendency to any type of bleeding (Table 2). (p< 0.001). Furthermore non-anticoagulated patients showed significant more skull fractures (p=0.002).

In all three analyses anticoagulation did not evidence as a significant factor, nor in mortality neither in GOS and KPS (p= 0.886; 0.926; 0.934). Significant factors were PT, age, radiological finding and neurological status on admission.

A better outcome, connoted survival, high GOS and high KPS is

Results

Overall

Over a period from January 2003 to September 2008 we treated a total of 293 patients meeting inclusion criteria. We examined a 100% of preinjury data. Follow up for the entire group was obtainable for 275 of 293 patients (93.9%), although we performed consequent data mining.

Of all patients, 48 (16.4%) received preinjury anticoagulation (group 1). The rest of the entire group, 245 patients (83.6%) was non anticoagulated patients (group 2).

Regarding the use of anticoagulants, 25 patients (52.1%) were using oral anticoagulation (OAC), and 23 (47.9%) antithrombotic agents (ATH); details of different medication see Table 1.

Prothrombin time was included in the evaluation, with ranges from 8 to 122. Mean PT in group 1 was 68.85 and 77.79 in group 2 (p= 0.008). There was one patient with PT 8 and one with 9.

Mean age of the study population was 49.3 years, with ranges from 1 to 91 years. Mean age in group 1 was 73.53 (range 42 – 91) years; mean age in group 2 was 44.67 (range 1 – 88) years (p< 0.001). Ninety three (31.7 %) patients were female and 200 (68.3 %) were male. In group 2, 69 of 245 patients were female (27.9 %), whereas a higher percentage, 24 of 48 (50 %) were female in group 1 (p= 0.004). In both categories we saw significant differences between anti and non-anticoagulated patients.

Comparing anticoagulated and non-anticoagulated patients concerning the neurological status on admission, there were significant differences between them. In group 2 most patients were without any deficit, rather group 1, where most of them were comatose and intubated on admission (Table 2) (p= 0.004).

A CT scan was obtained in all patients. Both groups showed differences in radiological findings. Anticoagulated patients had a trend to aSDH with a total of 70%, whereas patients without anticoagulation did not show a tendency to any type of bleeding (Table 2). (p< 0.001). Furthermore non-anticoagulated patients showed significant more skull fractures (p=0.002).

In all three analyses anticoagulation did not evidence as a significant factor, nor in mortality neither in GOS and KPS (p= 0.886; 0.926; 0.934). Significant factors were PT, age, radiological finding and neurological status on admission.

A better outcome, connoted survival, high GOS and high KPS is

Table 1: Medication.

<table>
<thead>
<tr>
<th>Oral anticoagulation</th>
<th>Antithrombotic agents</th>
</tr>
</thead>
<tbody>
<tr>
<td>Phenprocoumon 22 (88%)</td>
<td>Acetylsalicylic acid 18 (78.3%)</td>
</tr>
<tr>
<td>Acenocumarol 3 (12%)</td>
<td>Clopidogrel 1 (4.3%)</td>
</tr>
<tr>
<td>Combination 4 (17.4%)</td>
<td></td>
</tr>
</tbody>
</table>

Table 2: Results.
conditional upon to higher PT, young age, without neurological findings on admission and type of bleeding. Odds ratios and significance see Table 2. Worse Outcome is most affected by combined bleeding, high age and bad neurological condition on admission. Furthermore low PT, aSDH, ICH are predicting worse outcome.

Discussion

Today, neurosurgeons are faced to a higher number of elderly patients, and the number of elders under OAC or ATH is increasing. The reason is that evidence shows a benefit preventing thromboembolic events [11]. Although there is this benefit, we know that the risk of spontaneous or traumatic bleeding is higher under anticoagulation [11,12]. The overall risk of hemorrhagic complications has been calculated by van de Meer et al. as 16.5 per 100 treatment per year, major bleeds counting for 2.7 per 100 treatment per year [13]. So the aim of our study was to see differences in mortality and outcome between anticoagulated and non-anticoagulated patients. Further, we wanted to determine important parameters for patient’s outcome after TBI and surgical treatment.

Some previous studies had examined the effect of OAC or ATH on outcome after TBI. The results concerning the effect are quite different. Wojcik et al. and other authors did not show any differences in mortality [4,14,15]. On the other hand there is evidence showing differences in mortality and outcome [12,16,17]. All these studies combine conservative and surgical treatment and some merge acute trauma and chronically bleeding what leads to different outcome itself. In contrast this study included only operated patients and only acute TBI. The results show that anticoagulation itself is not a predicting factor for mortality and morbidity. But, anticoagulation cannot be seen as black and white, the important thing is the intensity of anticoagulation.

It is becoming increasingly clear that the risks of bleeding events are proportional to the intensity of anticoagulation [12,18-20]. Levine et al. [20] observed in several studies a higher risk of fatal bleeding with high-intensity oral anticoagulant (OAC) therapy. Pieracci et al. [15] found in their series that the degree of anticoagulation, but not use of an anticoagulative drug itself, predicts adverse outcome after traumatic brain injury. Cerebral hemorrhage increases dramatically if the INR is >4, the absolute risk being 2% [18]. Hyleck et al. [18] also found a doubling of risk with each 0.5 increase in PT. In this case the literature and our study got the same finding. The recent results find PT as one important factor. A patient with 1 point lower PT has the odds ratio 1.25 for a 1 step decreased GOS. Not seldom, patients are in a non-therapeutically range. Over anticoagulation is an obvious risk factor for hemorrhagic complications and should be avoided.

As our population ages and the majority of medical problems are diseases of the elderly (thrombembolic complications of atrial fibrillation, of deep venous thrombosis, vascular diseases, prostatic cardiac valves, and so on) the use of anticoagulant and antithrombotic agents is expected to rise [6].

Age has consistently proven to be one of the most important factors of outcome from brain trauma [6,21,22].

The overwhelming majority of patients receiving anticoagulation or anti-thrombotic therapy are the elderly (age over 65 years). Moreover, the response to anticoagulative agents is exaggerated with advancing age [23]. However, issues regarding indications and therapeutic ranges for the drugs remain disputed and are frequently not adjusted in relation to the aging process [3]. The risk/benefit equation of anticoagulation for the elderly seems more complex and differs from that for younger patients [3]. These things make age a confounding factor in Outcome. In the study of Cohen et al, mortality of brain trauma patients under anticoagulation in patients with GCS scores less than 8 was 91.5%, with GSC scores of 13 to 15 mortality was 80.6%. However, this seemingly excessive mortality must be questioned, considering that the average age in this series was 79 years and no calculation of this confounding factor has been performed [6]. This recent study had significant differences too, between anti and non-anticoagulated patient’s age, and we stratified the groups in the statistic model. What we saw that age is the important factor and not anticoagulation. The older the patient, the worse was the chance to survive or to be in a healthy condition.

Clinical status on admission turned out as one of the most important factors for outcome in our study. This confirms the findings of Cohen et al. who found a mortality rate of 87.8% for patients with GCS scores less than 8 [6].

High mortality of aSDH and ICH is described in many studies already from the early 60’s to the present [24,25]. Not only mortality, also outcome is influenced by the type of bleeding. Our results showed, that combined hemorrhage, aSDH and ICH cause a higher mortality and a worse outcome, especially ICH with an odds ratio of nearly 45 compared to epidural hematomas concerning mortality.

A significant difference in skull fractures between anticoagulated and non anticoagulated patients seems to be a sign for different type of injuries. Intracranial hemorrhage appears even in minor trauma in anticoagulated and especially over anticoagulated patients [6,8]. Our study has a lack of type and severity of trauma, but the differences in skull fractures seem to show differences in severity of trauma, compatible to literature.

Limitations and future questions

There are several limitations to this study that should be considered. First, our data were retrospectively abstracted from our hospital records, with no mechanism to validate the accuracy of measurements. Prehospital and admission GCS values as well as the reason for preinjury anticoagulation could not be found in a considerable part of patients, thus were not included in our calculations. Second, OAC and ATH were put together as one group, thus it is different medication. Statistical analysis in the subgroups of medication could not be performed due to small patient series in the subgroups. Finally, reversal of anticoagulation was not performed in a regular manner with strict dosage regime, even though clotting factor concentrates have been used in the majority of cases, further not in every patient with ATH medication a platelet function test was performed to prove, if they were responder.

Conclusion

Given the fact that TBI is the fifth leading cause of death in the age group where the use of anticoagulation is gaining popularity, it is highly likely that neurosurgeons and trauma surgeons will be confronted with the clinical scenario of traumatic brain injury in an anticoagulated patient on a regular basis. Therefore, outcome data for this patient group are highly warranted. Our results correlate strongly with previous suggestions that the prognosis of intracranial hemorrhage is predominantly influenced by the patient’s age, the clinical status, the compartment of bleeding and the degree of anticoagulation at the time of presentation. This underscores the importance of ongoing investigations as to the early reversal of anticoagulation as well as to optimal values of INR and PT in these patients, but most important is
that anticoagulation itself is not a predicting factor for outcome after TBI.

References